Oxidative stress to dopaminergic neurons as models of Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 1018, Issue , 2004, Pages 533-540

  Gille, G ^a   Hung, S T ^a   Reichmann, H ^b   Rausch, W D ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Coenzyme Q10; Dopamine agonists; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ANTIOXIDANT; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; BRAIN SLICE; CELL PROTECTION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RESPIRATORY CHAIN; SURVIVAL RATE; TISSUE CULTURE; TOXICOKINETICS;

ANIMALIA;

EID: 3242668754     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1296.066     Document Type: Conference Paper

References (18)

1. LE, W.D. & J. JANKOVIC. 2001. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 18: 389-396.
2. MAREK, K., J. SEIBYL, I. SHOULSON, et al. 2002. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287: 1653-1661.
3. CARVEY, P.M., S.O. MCGUIRE & Z.D. LING. 2001. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Rel. Disord. 7: 213-223.
4. GOMEZ-VARGAS, M., S. NISHIBA YASHI-ASANUMA, M. ASANUMA, et al. 1998. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790: 202-208.
5. NICKLAS, W.J., I. VYAS & R.E. HEIKKILA. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
6. HALLIWELL, B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716.
7. GILLE, G., W.D. RAUSCH, S.T. HUNG, et al. 2002. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J. Neural Transm. 109: 633-643.
8. STOPPINI, L., P.-A. BUCHS & D. MÜLLER. 1991. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Meth. 37: 173-182.
9. NAGATSU, T., K. OKA & T. KATO. 1979. Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography. J. Chromatogr. 163: 247-252.
10. KUGLER, P. 1988. Quantitative enzyme histochemistry in the brain. Histochemistry 90: 99-107.
11. FAHN, S. 1998. Welcome news about levodopa, but uncertainty remains. Ann. Neurol. 43: 551-555.
12. SCHAPIRA, A.H., J.M. COOPER, D. DEXTER, et al. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827.
13. ALAM, M. & W.J. SCHMIDT. 2002. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136: 317-324.
14. LANGSTON, J.W., L.S. FORNO, J. TETRUD, et al. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46: 598-605.
15. PRZEDBORSKI, S., V. JACKSON-LEWIS, U. MUTHANE, et al. 1993. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34: 715-723.
16. BEAL, M.F., R.T. MATTHEWS, A. TIELEMAN, et al. 1998. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 783: 109-114.
17. CHAN, T.S., S. TENG, J.X. WILSON, et al. 2002. Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1(NQO1). Free Radic. Res. 36: 421-427.
18. SHULTS, C.W., D. OAKES, K. KIEBURTZ, et al. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59: 1541-1550.